The knock on the company is going stale: this quarter's own facts cut against the standing doubt
The model's full reasoning — Q3 2023 call → NO我们根据指令分析。需要识别一个明确的、公司特定的疑虑,并且当前期间的实际运营证据是否明显反驳该疑虑。 从电话会议中,我们看到公司正在推出FUROSCIX,一个新产品。分析师的问题集中在处方量、每处方剂量、IDN合同、销售代表增加等。管理层讨论了收入增长、处方增长、新合同等。 疑虑可能是什么?可能是关于产品采用率、处方转化率、患者获取、支付方覆盖等。但电话会议中,管理层似乎很乐观,分析师的问题也多是询问细节,没有明显的负面疑虑。不过,有一个点:管理层提到“fill rate”为55%,且提到取消原因包括高自付费用。但整体上,公司处于早期商业化阶段,亏损扩大(净亏损从1020万增至1560万),但收入增长。分析师没有直接质疑公司能否盈利,但可能隐含。 再读:管理层说“我们仍然非常满意FUROSCIX的推出轨迹”,并提到新增销售代表、IDN合同等。分析师的问题如“处方量增加但每处方剂量也增加”等,没有明显疑虑。 也许疑虑是“公司能否实现盈利”或“产品需求是否可持续”?但电话会议中,管理层没有直接回应这种疑虑,而是展示增长数据。然而,指令要求“standing knock”在电话会议中可见,即分析师或管理层提及的疑虑。例如,分析师问“处方量增加但每处方剂量也增加”可能暗示对剂量可持续性的担忧?但这不是明确的疑虑。 再考虑:管理层提到“GTN为21%”,并说“我们预计会随着合同增加而上升”,这可能暗示对利润率担忧。但这不是主要。 或许疑虑是“公司依赖单一产品”或“商业化初期的不确定性”。但电话会议中,管理层积极回应。 仔细看,分析师Nik Gasic问“IDN直接购买协议的规模和频率”,这可能是对收入来源的担忧。但管理层回答积极。 另一个可能:管理层提到“我们无法看到IDN的处方量”,这可能引起对数据透明度的担忧,但未明确。 指令要求“clearly weighing on how this company is perceived”,即一个明显的疑虑。在电话会议中,没有分析师直接说“我们担心亏损”或“我们担心需求”。但管理层在开场白中说“我们相信专家们正在迅速获得处方信心”,这暗示可能有人怀疑。 也许疑虑是“产品采用速度慢”或“处方转化率低”?但管理层给出了具体数字:处方从631增至1119,填充率从52%增至55%,这些是积极证据。 再读:管理层说“我们预计填充率将继续提高”,这暗示当前填充率可能被视为低。但分析师没有直接质疑。 或许疑虑是“公司现金消耗”或“融资需求”?但管理层没有提及融资,现金从118.4降至90.2,但这是正常。 我认为没有明显的、公司特定的、预先存在的疑虑在电话会议中被明确提及。分析师的问题都是中性的,管理层也自信。因此,答案应为NO。 但指令要求“the doubt must be specific to this company's situation”,并且“read as something that predates this quarter”。在电话会议中,没有这样的表述。管理层提到“我们之前说过要达到75%的患者有固定共付”,这可能是对支付方覆盖的担忧,但那是目标。 或许疑虑是“公司能否获得支付方覆盖”?但管理层宣布了新的合同,这反驳了。 总之,没有明显的疑虑。因此,答案NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| PRA | ProAssurance Corporation | Q1 2024 | 2024-05-11 | D |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CLSD | Clearside Biomedical, Inc. | Q3 2022 | 2022-11-09 | C |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| ULBI | Ultralife Corporation | Q3 2016 | 2016-10-29 | C+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.